乳腺癌原发灶及淋巴结转移灶中ER、PR表达及临床意义  

Expressions and clinical significance of ER,PR in breast cancer and lymph-node metastatic tumor

作　　者：宁殿宾[1] 曹文庆[1] 赵玉哲[1] 王跃欣[1] 张静[1] 

机构地区：[1]河北省人民医院,石家庄050051

出　　处：《山东医药》2009年第37期19-20,共2页Shandong Medical Journal

基　　金：河北省科学技术研究与发展指导计划项目(062761911)

摘　　要：目的探讨乳腺癌原发灶和淋巴结转移灶中雌激素受体(ER)、孕激素受体(PR)表达及其与肿瘤分期、病理类型的关系。方法采用免疫组化SP法,检测36例乳腺癌术后患者原发灶和淋巴结转移灶中的ER、PR表达。结果乳腺癌原发灶中的ER阳性率69.5%、PR阳性率55.6%,淋巴结转移灶中分别为63.9%、44.4%;原发灶和淋巴结转移灶中的ER、PR表达呈正相关(P均<0.01),与肿瘤分期、病理类型无明显相关性(P均<0.01)。结论判断乳腺癌患者的预后应综合考虑其原发灶和转移灶的生物学特性。Objective To investigate the protein expressions of estrogen receptor （ ER ）, progesterone receptor（PR） in breast cancer and their lymph-node metastatic tumor and the correlation between ER, PR and tumor staging, pathological type. Methods High sensitive S-P immunohistochemical method was used to detect the protein expressions of ER, PR in primary lesion or metastasis in 36 breast cancers. Results ER positive rate in primary lesion was 69.5%, PR positive rate in primary lesion was 55.6%. ER and PR positive rate in metastasis was separately 63.9% , 44.4%. The expressions of ER were positively associated with PR in primary lesion and lymphatic metastasis（ P 〈 0.01 ）, and were not correlated with tumor staging and pathological type. Conclusion Biological characteristic in primary lesion and metastasis of breast cancers should be synthetically considered to predict the prognosis of patients.

关 键 词：乳腺肿瘤 受体 雌激素 受体 孕激素 

分 类 号：R737.9[医药卫生—肿瘤]